Private Capital Advisors Inc. lowered its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 97.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,811 shares of the financial services provider’s stock after selling 77,946 shares during the period. Private Capital Advisors Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $604,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in IBB. Paloma Partners Management Co lifted its holdings in shares of iShares Nasdaq Biotechnology ETF by 1,643.3% in the second quarter. Paloma Partners Management Co now owns 323,373 shares of the financial services provider’s stock valued at $35,513,000 after purchasing an additional 304,824 shares in the last quarter. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of iShares Nasdaq Biotechnology ETF by 54.0% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 585,506 shares of the financial services provider’s stock valued at $64,300,000 after purchasing an additional 205,200 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $18,741,000. Cornerstone Wealth Management LLC bought a new position in shares of iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $1,420,000. Finally, Natixis lifted its holdings in shares of iShares Nasdaq Biotechnology ETF by 8.7% in the second quarter. Natixis now owns 1,250,000 shares of the financial services provider’s stock valued at $137,275,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.
Get iShares Nasdaq Biotechnology ETF alerts:Shares of IBB stock traded up $2.17 during trading hours on Friday, reaching $111.25. The company had a trading volume of 2,547,196 shares, compared to its average volume of 2,533,755. iShares Nasdaq Biotechnology ETF has a 12 month low of $100.22 and a 12 month high of $122.97.
The business also recently announced a quarterly dividend, which was paid on Tuesday, October 2nd. Stockholders of record on Thursday, September 27th were issued a $0.0324 dividend. The ex-dividend date of this dividend was Wednesday, September 26th. This represents a $0.13 dividend on an annualized basis and a dividend yield of 0.12%.
About iShares Nasdaq Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Story: Moving Average (MA)
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
No comments:
Post a Comment